Acuitive Technologies introduces Citregraft, a unique bone graft substitute designed to bind proteins and enhance regeneration
ALLENDALE, N.J., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Acuitive Technologies® commercializes Citregraft™, with its first use in a surgical case, performed on November 4th, 2025.
Bone graft substitutes are used to repair defects from trauma, infection, tumor removal, and reconstructive surgery. However, poor handling, low biological activity, variable resorption rate, and inadequate integration limit their effectiveness.
Leveraging the benefits of citrate in bone anatomy and physiology, Acuitive Technologies developed Citregen®, a citrate-based polymer technology that mimics natural bone chemistry and supplies the energy needed for regeneration. Exclusively made with Citregen and bioactive glass, Citregraft is a highly porous and bioactive synthetic bone graft substitute designed to interact with proteins to regenerate bony voids within the skeletal system.
Citregraft benefits include:
- Bioactive formulation to improve graft integration
- Easily morselized to fill and hold its position within irregular defects
- Absorbs 5 times its weight in fluids
- Synergizes with bone marrow aspirate (BMA) to bind proteins
-
Citrate increases cell energy for tissue regeneration
“Citregraft was easily morselized to fill my tibial harvest site during BPTB ACL reconstruction. After soaking it in saline, it readily absorbed blood and growth factors from the harvest site and conformed perfectly to the defect,” said Robin Gehrmann, MD.
Citregraft overcomes the limitations of conventional bone graft substitutes by improving handling, liquid uptake, and protein binding. Its demonstrated bioactivity and ability to bind proteins establish Citregraft as a viable option for surgeons seeking innovative solutions for bone repair and regeneration.
Media Contact
Thomas McCarthy
Acuitive Technologies, Inc.
tmccarthy@acuitivetech.com
https://www.acuitivetech.com/
Data on file, TM251008, at Acuitive Technologies Inc., Allendale, NJ, USA
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/233ecf43-c685-4d77-ba95-b1a49b14eecb
Citregraft
Protein Binding Bioactive Scaffold
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
